AMGN vs. VRTX, REGN, GILD, MRNA, SGEN, BIIB, ALNY, BMRN, NBIX, and INCY
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Moderna (MRNA), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Incyte (INCY). These companies are all part of the "medical" sector.
Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Amgen has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vertex Pharmaceuticals had 8 more articles in the media than Amgen. MarketBeat recorded 31 mentions for Vertex Pharmaceuticals and 23 mentions for Amgen. Vertex Pharmaceuticals' average media sentiment score of 0.80 beat Amgen's score of 0.58 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Vertex Pharmaceuticals received 29 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.66% of users gave Vertex Pharmaceuticals an outperform vote while only 72.41% of users gave Amgen an outperform vote.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Amgen's net margin of 12.74%. Amgen's return on equity of 156.21% beat Vertex Pharmaceuticals' return on equity.
Amgen currently has a consensus target price of $305.65, suggesting a potential downside of 0.07%. Vertex Pharmaceuticals has a consensus target price of $438.62, suggesting a potential downside of 3.67%. Given Amgen's stronger consensus rating and higher possible upside, equities analysts clearly believe Amgen is more favorable than Vertex Pharmaceuticals.
Summary
Vertex Pharmaceuticals beats Amgen on 10 of the 18 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
